2015 ASCO Annual meeting | "Lobular" related abstracts

The annual ASCO cancer conference is taking place now (May 29 - June 2, 2015) in Chicago, Illinois.

You can browse all Breast Cancer abstracts and sessions using this link.

I did a simple search using the keyword "Lobular" and below are the 23 abstracts generated.

Clearly, most of these are focused on other topics and only mention Lobular.

1. 21-gene recurrence score assay (RS) and impact on adjuvant chemotherapy (CTx) use among lobular (L) and ductal (D) histology hormone receptor positive (HR+) early breast cancers (EBC).
...score assay (RS) and impact on adjuvant chemotherapy (CTx) use among lobular (L) and ductal (D) histology hormone receptor positive...
URL: http://abstracts.asco.org/156/AbstView_156_147155....

2. Metastatic pattern of invasive lobular carcinoma.
...presented at the Meeting, can be found online only. Metastatic pattern of invasive lobular carcinoma.Sub-category: ER+ Category: Breast Cancer - HER2/ER...
URL: http://abstracts.asco.org/156/AbstView_156_150409....

3. Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.
...28 vs. 20%; p= 0.021) and a higher proportion of lobular carcinomas (22.4 vs. 9.5%; p< 0.001) compared to...
URL: http://abstracts.asco.org/156/AbstView_156_149959....

4. FLT-PET (Fluorothymidine) and Ki-67 to measure effects of a short course of aromatase inhibitor therapy in ER+ breast cancer patients.
...postmenopaual patients, and in (17) ductal vs (6) lobular patients were similar. Conclusions: FLT PET measured endocrine treatment induced metabolic changes...
URL: http://abstracts.asco.org/156/AbstView_156_152145....

5. Multi-institutional evaluation of women at high-risk for developing breast cancer.
...include family history, BRCA mutations and biopsies with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS). Several institutions have registries of these high-risk...
URL: http://abstracts.asco.org/156/AbstView_156_151693....

6. Contralateral breast cancer (CBC) incidence and risk in New Zealand (NZ).
...immediate relative/s was not (HR 1.2, p= 0.53). Lobular histology was not associated with CBC development (HR1.4, p= 0.45)...
URL: http://abstracts.asco.org/156/AbstView_156_150564....

7. Axillary recurrences in early breast cancer patients treated with sentinel node biopsy. Experience at the Instituto Nacional de Enfermedades Neoplasicas.
...and T3(5.5%) .Ductal(90%),lobular(4.5%) .Luminal A...
URL: http://abstracts.asco.org/156/AbstView_156_152261....

8. Quantitation of CD11c+ dendritic cells normal breast tissue and benign breast disease.
...fibrocystic (FC). Immunohistochemical CD11c staining was performed to identify dendritic cells; lobular CD11c+ cells were digitally quantitated on a per lobule basis by the CD11c...
URL: http://abstracts.asco.org/156/AbstView_156_152377....

9. Cyclin D1 as a biomarker of response to fulvestrant (F) in hormone receptor-positive (HR+) breast cancer (BC).
...The remaining pt had moderately differentiated (MD) invasive ductal & lobular carcinoma (mixed). 50% of HCD1 pts had PD tumors while...
URL: http://abstracts.asco.org/156/AbstView_156_153426....

10. Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).
...Palpable (%) 20.6% 22.4% 0.761 Invasive lobular histology (%) 11.0% 7.8% 0.744 DCIS component...
URL: http://abstracts.asco.org/156/AbstView_156_153165....

11. Could tumor growth rate provide useful information to predict the efficacy of eribulin?
...PFS and OS. Results: Histological sub-types were: ductal carcinomas 86%, lobular carcinomas 9% and other 5%. Hormonal receptor status was positive in...
URL: http://abstracts.asco.org/156/AbstView_156_152687....

12. Response and neurologic toxicity to taxano regarding to CYP2C8*3 and CYP2C8*2 polymorphisms in Peruvian breast cancer cases.
...Infiltrating ductal carcinoma (94.8%) were most frequent followed by Infiltrating lobular carcinoma (5.2%); 87.1% completed 12 courses of paclitaxel...
URL: http://abstracts.asco.org/156/AbstView_156_152382....

13. Neoadjuvant endocrine therapy in locally advanced hormone receptor positive (HR+) breast cancer (BC) in a low-resource, middle-income setting (Guatemala).
...Menopausal status Pre 9 Post 26 Histology Ductal 31 Lobular 3 Micropapillary 1 Clinical stage IIB 5 IIIA 22 IIIB 7 IIIC 1 Hormone...
URL: http://abstracts.asco.org/156/AbstView_156_150513....

14. Contralateral prophylactic mastectomy (CPM) use and utility in New Zealand (NZ) breast cancer patients.
...in patients with multifocal cancer (68.9%, cf. 18%), lobular carcinoma (18.6%, cf. 11%), and tumors of...
URL: http://abstracts.asco.org/156/AbstView_156_150447....

15. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients.
...negative factors included multifocality on imaging (OR 0.67, p= 0.045), lobular histology (OR 0.53, p< .0001), PR+...
URL: http://abstracts.asco.org/156/AbstView_156_148436....

16. A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study.
...Overall, 82.8% of patients were diagnosed with ductal breast cancer (lobular 10.7% others 6.5%), 79.9% were ER/PgR+...
URL: http://abstracts.asco.org/156/AbstView_156_147835....

17. A multi-center prospective study of radiofrequency ablation without surgical excision for small breast carcinomas.
...MRI. Exclusion criteria include receiving of preoperative chemotherapy, or the presence of invasive lobular carcinoma or invasive ductal carcinoma with suspicious EIC. After confirmation that the standard...
URL: http://abstracts.asco.org/156/AbstView_156_145254....

18. Identification of potential salivary biomarkers for the early diagnosis of breast cancer.
...had invasive ductal carcinoma, 14 had ductal carcinoma in situ and 3 had invasive lobular carcinoma. Fourteen patients were clinical stage 0, 43 were stage I...
URL: http://abstracts.asco.org/156/AbstView_156_148685....

19. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.
...7.7% vs 8.2%, respectively). Histopathological diagnosis of invasive ductal and lobular cancers were similar (p= 0.965), as well as tumor grades...
URL: http://abstracts.asco.org/156/AbstView_156_148885....

20. Signet ring cell carcinoma of breast: Single center experience.
...with mixed histology, co-existed histology was invasive ductal carcinoma in 9 patients and invasive lobular carcinoma in 6 patients. Median follow up was 27 months. Seven patients...
URL: http://abstracts.asco.org/156/AbstView_156_144286....

21. TARGIT-U.S.: A registry trial of targeted intraoperative radiation therapy following breast-conserving surgery.
...risk features are detected on final pathology (EIC, positive node, or invasive lobular histology) the patient will undergo additional EBRT (excluding boost)...
URL: http://abstracts.asco.org/156/AbstView_156_150402....

22. Circulating tumor cells (CTCs) in breast cancer without distant metastases.
...breast cancer patients were recruited: 23- infiltrating ductal carcinoma, 1- infiltrative lobular carcinoma, 1- mixed cancer. CellSearch Veridex system, Janssen...
URL: http://abstracts.asco.org/156/AbstView_156_149430....

23. Pattern and predictors of relapse among early breast cancer patients as seen in a low-income setting: Experience from Nairobi.
...range 25-82. Ductal carcinoma constituted 81 of 88 cases (92%), lobular carcinoma 6 (6.8%). Sixty-eight were evaluable for stage based on...
URL: http://abstracts.asco.org/156/AbstView_156_146872....

Haha. I drive her crazy. Seriously. She has a positive outlook on life and cautiously rejects the idea of recurrence.
I've lingered on these forums long enough to know that anything can happen and intelligent patients who educate themselves can do a great deal to improve their prognosis. Like many of you, I recognize that lobular is inadequately represented. MmeJ's thread "ILC - The Odd One Out?" clearly underscores this. Making matters more challenging is the complete lack of ILC data for pre menopausal women.
I've learned so much from everyone here. Being analytical, I enjoy the research and giving back. I'm striving to be an advocate for her and others affected by ILC.

Right now, I'm writing an email to the "Center for Molecular Immunology" in Cuba to explore their breast cancer vaccine / immunotherapy program. As U.S. relations with Cuba thaw, the unexpected byproduct is the introduction of Cuban-developed cancer vaccines. Apparently, Cuba has a clever group of immunotherapy cancer researchers and the 50+ year U.S. embargo has prevented access to these therapies.
Andrew Cuomo, Governor of New York, visited Havana in April 2015 to help negotiate bringing Cuba's revolutionary Lung cancer vaccine, "Cimavax", to Roswell Park Cancer Institute in Buffalo, NY. Here's an article that discusses this: "Americans could soon be thanking Fidel Castro for their revolutionary cancer drugs".
Ironically, Governor Cuomo's partner, Sandra Lee, just announced she has breast cancer (I believe DCIS and/or Ductal... not really sure).

Quick research shows that Cuba has a Phase II / III trial on a breast cancer vaccine called:
Therapeutic vaccine N-glycolyl GM3.
NGcGM3 or NGc-GM3 / VSSP (N-glycolyl GM3 for breast cancer immunotherapy).
NeuGcGM3/VSSP/Montanide ISA51 is a therapeutic formulation that induces an immunological response in breast cancer patients.
It's not clear if this originates from Cuba or if other countries are involved in development. Clinicaltrials.gov didn't seem to generate anything, so it might be exclusive to Cuba.

Anyway... I've deviated from the purpose of this thread.

ASCO 2015!!!

Who are the Lobular patient advocate(s)?
Attend ASCO as a Patient Advocate

Not to derail my own thread, the charitable organization called "Stand Up To Cancer" was started by Laura Ziskin, Katie Couric and others. Laura Ziskin (here's her wiki), a prominent American film producer, was diagnosed with Stage 3 ILC in 2004.
Although she passed from the disease in 2011, I wonder if her organization has been channeling any of the $370 million its raised towards Lobular research programs.
Since the founders came from the entertainment industry, there's been a number of celebrities that donate their "Star Power" to the charitable group. It would be a "win win" for Rita Wilson / Tom Hanks to sync up with this charity, imo.